# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to ...
Maxim Group analyst Naz Rahman initiates coverage on Alimera Sciences (NASDAQ:ALIM) with a Buy rating and announces Price Ta...
HC Wainwright & Co. analyst Yi Chen maintains Alimera Sciences (NASDAQ:ALIM) with a Buy and raises the price target from...
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.07) per share. This is a 87.04 percent increase over losses of ...
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...
Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to ...